Khaled Mahmoud Abouelkhair

@mans.edu.eg

Associated professor clinical oncology/ Mansoura Faculty of Medicine
Mansoura university

Khaled Mahmoud Abouelkhair


                  Download Compact PDF  
https://researchid.co/abulkhair

RESEARCH, TEACHING, or OTHER INTERESTS

Oncology, Gastroenterology
7

Scopus Publications

300

Scholar Citations

7

Scholar h-index

6

Scholar i10-index

Scopus Publications

  • Association of PD-L1 expression with adverse pathological features in adult diffuse astrocytoma
    Rania K. Elsaid, Maha M. Abuhashim, Sylvia A. Ashamallah, Khaled M. Abouelkhair, Marwa M. Zaki
    Egyptian Journal of Basic and Applied Sciences, 2025
  • Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
    Riccardo Giampieri, Alessandra Mandolesi, Khaled M Abouelkhair, Cristian Loretelli, Michela Del Prete, Luca Faloppi, Bianconi Maristella, Ezzeldin M Ibrahim, Marina Scarpelli, Stefano Cascinu, Mario Scartozzi
    Journal of Translational Medicine, 2015
    BACKGROUND: The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might be able to predict patients' clinical outcome more accurately than RAS status alone. METHODS: K-RAS (exons 2, 3, 4) wild type colorectal cancer patients, candidates to second/third-line cetuximab with chemotherapy were prospectively allocated into 2 groups on the basis of their profile: favourable (BRAF and PIK3CA exon 20 wild type, EGFR GCN ≥ 2.6, HER-3 Rajkumar score ≤ 8, IGF-1 immunostaining < 2) or unfavourable (any of the previous markers altered or mutated). After the introduction of N-RAS status (exons 2, 3, 4) only RAS wild type patients were considered eligible. Primary aim was response rate (RR). To detect a difference in terms of RR among patients with an unfavourable profile (estimated around 25%) and patients with a favourable profile (estimated around 60%), with a probability alpha of 0.05 and beta of 0.05, required sample size was 46 patients. Secondary endpoints were progression free survival (PFS) and overall survival (OS). RESULTS: Forty-six patients were enrolled. Seventeen patients (37%) were allocated to the favourable and 29 patients (63%) to the unfavourable profile. RR in the favourable and unfavourable group was 11/17 (65%) and 2/29 (7%) (p = 0.007) respectively. The favourable group also showed an improved PFS (8 months vs. 3 months, p < 0.0001) and OS (15 months vs. 6 months, p < 0.0001). CONCLUSIONS: Our results suggest that prospective selection of optimal candidates for cetuximab treatment is feasible and may be able to improve clinical outcome.
  • Sunitinib adverse events in metastatic renal cell carcinoma: A meta-analysis
    Ezzeldin M. Ibrahim, Ghieth A. Kazkaz, Khaled M. Abouelkhair, Ali M. Bayer, Osama A. Elmasri
    International Journal of Clinical Oncology, 2013
  • Increased risk of second lung cancer in Hodgkin's lymphoma survivors: A meta-analysis
    Ezzeldin M. Ibrahim, Ghieth A. Kazkaz, Khaled M. Abouelkhair, Mubarak M. Al-Mansour, Turki M. Al-Fayea, Meteb Al-Foheidi, Ali M. Bayer, Osama A. Elmasri
    Lung, 2013
  • Risk of second breast cancer in female Hodgkin's lymphoma survivors: A meta-analysis
    Ezzeldin M Ibrahim, Khaled M Abouelkhair, Ghieth A Kazkaz, Osama A Elmasri, Meteb Al-Foheidi
    BMC Cancer, 2012
    BACKGROUND: Women treated for Hodgkin's lymphoma (HL) have an elevated risk of developing second breast cancer (SBC) compared with the general population. We planned this meta-analysis to quantify the long-term risk of SBC and analyze the contributing risk factors among HL survivors. METHODS: According to predefined selection criteria, literature search identified 34 studies that were included in the analyses. RESULTS: After eliminating overlapping or duplicate data, 957 incidences of SBC were encountered in 24,505 females with HL over a median follow-up of 14.9 years. The medians: age at the diagnosis of HL, age at diagnosis of SBC, and latency since HL treatment to the development of SBC were 23.7, 35.0, and 17.7 years, respectively. The pooled relative risk (RR) of SBC was 8.23 (95% CI, 5.43-12.47, I² = 96%), with a median absolute excess rate of 22.9 per 10,000 person-years. The RR was found inversely related to age at diagnosis of HL with the highest rate (68.7; [95%CI, 28.08-168.11], I² = 79%), occurred in young patients (≤ 15 years old), where the RR in older women (≥ 40 years old) was not significant (0.55; [95% CI, 0.09-3.52]). Analysis of RR by 5-year increments since the treatment of HL showed that the risk was highest after 15-19 years of latency (13.87; [95% CI, 7.91-24.30], I² = 89%). Analysis of the effect of treatment modalities showed that the RR rates were (4.70; [95% CI, 3.28-6.75], I² = 74%), (5.65; [95%CI, 2.94-10.88], I² = 91%), and (1.19; [95% CI, 0.50-2.82], I2 = 65%), for radiotherapy (RT) only, combined RT and chemotherapy (CT), and CT only, respectively. To investigate the demonstrated heterogeneity, meta-regression analysis was performed when feasible. In most such analyses, the natural logarithm of RR was inversely associated with age at HL diagnosis. CONCLUSIONS: We conclude that, the current meta-analysis provided the most recent comprehensive estimate of the risk of SBC in a broad-range of HL survivors. Younger age at diagnosis proved to be a dominant risk factor. The obtained results would serve providing breast cancer screening recommendations for HL survivors.
  • Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: A meta-analysis of randomized clinical trials
    Ezzeldin M. Ibrahim, Khaled M. Abouelkhair
    Medical Oncology, 2011
  • Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: A meta-analysis of randomized controlled trials
    Ezzeldin M. Ibrahim, Khaled M. Abouelkhair, Osama A. Al-Masri, Najeeb C. Chaudry, Ghieth A. Kazkaz
    Lung, 2011

RECENT SCHOLAR PUBLICATIONS

  • A Randomized, Double-Blind, Placebo Controlled Trial of Omeprazole as A Promising Drug for Protection Against Chemo Induced Neuropathy
    AKM Sadek AM, Hegazy SK, Hamada ZM
    Int J Drug Deliv Technol 16 (1s), 862-873 , 2026
    2026
  • Impact of consolidation chemotherapy after concurrent chemoradiation in locally advanced cervical cancer—a randomized controlled trial
    H Elghamery, GE Eladawei, H Wahba, R Hemida, KM Abouelkhair
    Oncology in Clinical Practice 22 , 2026
    2026
  • Association of PD-L1 expression with adverse pathological features in adult diffuse astrocytoma
    RK Elsaid, MM Abuhashim, SA Ashamallah, KM Abouelkhair, MM Zaki
    Egyptian Journal of Basic and Applied Sciences 12 (1), 526-541 , 2025
    2025
  • 633ep- Palbociclib + ET in Premenopausal women versus Combined Chemotherapy with HR+/Her2- Breast Cancer with Visceral Metastases
    MD Abdallah Ahmad Khalil, Khaled Abouelkhair, Mona Foda
    ESMO breast , 2025
    2025
  • Palbociclib plus endocrine therapy in Premenopausal women in HR+/Her2-Breast Cancer with Visceral Metastases versus Combined Chemotherapy
    MD Abdallah Ahmad Khalil, Khaled Abouelkhair, Mona Foda
    Journal of Carcinogenesis 24 (3), 635-642 , 2025
    2025
  • 190P The role of liver biopsy for unsettled HCC diagnosis: A single-center experience
    A El Sergany, W Elkashef, O Abdallah, O Elmetwally, RA Zayed, F Sabry, ...
    Annals of Oncology 35, S86 , 2024
    2024
    Citations: 1
  • Treatment Outcome and Prognostic factors of Glioblastoma Multiforme
    AMF Ahmed EMA, Abdalla EA, Abouelkhair KM
    SECI Oncology 4, 344-352 , 2024
    2024
  • MDCT evaluation of hepatic manifestations in Malignant hematological disorders
    A El-Badrawy, A Tawfik, G Saleh, M Abdel-Naby, H Ghazy, Z Emarah, ...
    CARDIOVASCULAR DISORDER AND MEDICINE Учредители: Science Repository OU, 1-6 , 2020
    2020
    Citations: 1
  • Science Repository
    A El-Badrawy, A Tawfik, G Saleh, M Abdel-Naby, H Ghazy, Z Emarah, ...
    2020
  • The additive role of 1H-magnetic resonance spectroscopic imaging to ensure pathological complete response after neoadjuvant chemotherapy in breast cancer patients
    D Bayoumi, M Zaky, D Ibrahim, A Abdallah, K Abouelkhair
    Polish journal of radiology 84, 570-580 , 2019
    2019
    Citations: 7
  • Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
    R Giampieri, A Mandolesi, KM Abouelkhair, C Loretelli, M Del Prete, ...
    Journal of translational medicine 13 (1), 140 , 2015
    2015
    Citations: 8
  • Molecular selection for colorectal cancer (CRC) patients receiving cetuximab: Final results of a prospective study.
    M Scartozzi, R Giampieri, M Del Prete, A Mandolesi, L Faloppi, ...
    Journal of Clinical Oncology 33 (3_suppl), 596-596 , 2015
    2015
  • Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis
    EM Ibrahim, GA Kazkaz, KM Abouelkhair, AM Bayer, OA Elmasri
    International journal of clinical oncology 18 (6), 1060-1069 , 2013
    2013
    Citations: 48
  • Evaluation of the inferior pedicle therapeutic mammoplasty as a primary procedure for upper quadrant breast cancer
    A Denewer, W Elsoudi, O Hussein, A Khater, W El-sadda, K Abouelkher
    EUROPEAN JOURNAL OF CANCER 49, S464-S464 , 2013
    2013
  • Molecular biomarkers for a prognostic stratification of K-RAS wild type colorectal cancer patients receiving irinotecan-cetuximab: Preliminary results of a prospective study
    M Scartozzi, R Giampieri, A Mandolesi, KM Abouelkhair, C Loretelli, ...
    EUROPEAN JOURNAL OF CANCER 49, S562-S562 , 2013
    2013
  • Prognostic stratification of k-RAS wild type colorectal cancer patients receiving irinotecan-cetuximab treatment: Preliminary results of a prospective study.
    M Scartozzi, R Giampieri, A Mandolesi, KM Abouelkhair, C Loretelli, ...
    Journal of Clinical Oncology 31 (15_suppl), 3591-3591 , 2013
    2013
  • Increased risk of second lung cancer in Hodgkin’s lymphoma survivors: a meta-analysis
    EM Ibrahim, GA Kazkaz, KM Abouelkhair, MM Al-Mansour, TM Al-Fayea, ...
    Lung 191 (1), 117-134 , 2013
    2013
    Citations: 58
  • Evaluation of inferior pedicle therapeutic mammoplasty as a primary procedure for upper quadrants early breast cancer
    A Denewer, W Elnahas, O Hussein, A Khater, W El-Sadda, K Abouelkher
    Adv Breast Cancer Res 2 (3), 86-90 , 2013
    2013
    Citations: 12
  • Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis
    EM Ibrahim, KM Abouelkhair, GA Kazkaz, OA Elmasri, M Al-Foheidi
    BMC cancer 12 (1), 197 , 2012
    2012
    Citations: 97
  • Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials
    EM Ibrahim, KM Abouelkhair
    Medical Oncology 28 (Suppl 1), 310-317 , 2011
    2011
    Citations: 23

MOST CITED SCHOLAR PUBLICATIONS

  • Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis
    EM Ibrahim, KM Abouelkhair, GA Kazkaz, OA Elmasri, M Al-Foheidi
    BMC cancer 12 (1), 197 , 2012
    2012
    Citations: 97
  • Increased risk of second lung cancer in Hodgkin’s lymphoma survivors: a meta-analysis
    EM Ibrahim, GA Kazkaz, KM Abouelkhair, MM Al-Mansour, TM Al-Fayea, ...
    Lung 191 (1), 117-134 , 2013
    2013
    Citations: 58
  • Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis
    EM Ibrahim, GA Kazkaz, KM Abouelkhair, AM Bayer, OA Elmasri
    International journal of clinical oncology 18 (6), 1060-1069 , 2013
    2013
    Citations: 48
  • Cetuximab-based therapy is effective in chemotherapy-naive patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials
    EM Ibrahim, KM Abouelkhair, OA Al-Masri, NC Chaudry, GA Kazkaz
    Lung 189 (3), 193-198 , 2011
    2011
    Citations: 45
  • Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials
    EM Ibrahim, KM Abouelkhair
    Medical Oncology 28 (Suppl 1), 310-317 , 2011
    2011
    Citations: 23
  • Evaluation of inferior pedicle therapeutic mammoplasty as a primary procedure for upper quadrants early breast cancer
    A Denewer, W Elnahas, O Hussein, A Khater, W El-Sadda, K Abouelkher
    Adv Breast Cancer Res 2 (3), 86-90 , 2013
    2013
    Citations: 12
  • Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
    R Giampieri, A Mandolesi, KM Abouelkhair, C Loretelli, M Del Prete, ...
    Journal of translational medicine 13 (1), 140 , 2015
    2015
    Citations: 8
  • The additive role of 1H-magnetic resonance spectroscopic imaging to ensure pathological complete response after neoadjuvant chemotherapy in breast cancer patients
    D Bayoumi, M Zaky, D Ibrahim, A Abdallah, K Abouelkhair
    Polish journal of radiology 84, 570-580 , 2019
    2019
    Citations: 7
  • 190P The role of liver biopsy for unsettled HCC diagnosis: A single-center experience
    A El Sergany, W Elkashef, O Abdallah, O Elmetwally, RA Zayed, F Sabry, ...
    Annals of Oncology 35, S86 , 2024
    2024
    Citations: 1
  • MDCT evaluation of hepatic manifestations in Malignant hematological disorders
    A El-Badrawy, A Tawfik, G Saleh, M Abdel-Naby, H Ghazy, Z Emarah, ...
    CARDIOVASCULAR DISORDER AND MEDICINE Учредители: Science Repository OU, 1-6 , 2020
    2020
    Citations: 1
  • A Randomized, Double-Blind, Placebo Controlled Trial of Omeprazole as A Promising Drug for Protection Against Chemo Induced Neuropathy
    AKM Sadek AM, Hegazy SK, Hamada ZM
    Int J Drug Deliv Technol 16 (1s), 862-873 , 2026
    2026
  • Impact of consolidation chemotherapy after concurrent chemoradiation in locally advanced cervical cancer—a randomized controlled trial
    H Elghamery, GE Eladawei, H Wahba, R Hemida, KM Abouelkhair
    Oncology in Clinical Practice 22 , 2026
    2026
  • Association of PD-L1 expression with adverse pathological features in adult diffuse astrocytoma
    RK Elsaid, MM Abuhashim, SA Ashamallah, KM Abouelkhair, MM Zaki
    Egyptian Journal of Basic and Applied Sciences 12 (1), 526-541 , 2025
    2025
  • 633ep- Palbociclib + ET in Premenopausal women versus Combined Chemotherapy with HR+/Her2- Breast Cancer with Visceral Metastases
    MD Abdallah Ahmad Khalil, Khaled Abouelkhair, Mona Foda
    ESMO breast , 2025
    2025
  • Palbociclib plus endocrine therapy in Premenopausal women in HR+/Her2-Breast Cancer with Visceral Metastases versus Combined Chemotherapy
    MD Abdallah Ahmad Khalil, Khaled Abouelkhair, Mona Foda
    Journal of Carcinogenesis 24 (3), 635-642 , 2025
    2025
  • Treatment Outcome and Prognostic factors of Glioblastoma Multiforme
    AMF Ahmed EMA, Abdalla EA, Abouelkhair KM
    SECI Oncology 4, 344-352 , 2024
    2024
  • Science Repository
    A El-Badrawy, A Tawfik, G Saleh, M Abdel-Naby, H Ghazy, Z Emarah, ...
    2020
  • Molecular selection for colorectal cancer (CRC) patients receiving cetuximab: Final results of a prospective study.
    M Scartozzi, R Giampieri, M Del Prete, A Mandolesi, L Faloppi, ...
    Journal of Clinical Oncology 33 (3_suppl), 596-596 , 2015
    2015
  • Evaluation of the inferior pedicle therapeutic mammoplasty as a primary procedure for upper quadrant breast cancer
    A Denewer, W Elsoudi, O Hussein, A Khater, W El-sadda, K Abouelkher
    EUROPEAN JOURNAL OF CANCER 49, S464-S464 , 2013
    2013
  • Molecular biomarkers for a prognostic stratification of K-RAS wild type colorectal cancer patients receiving irinotecan-cetuximab: Preliminary results of a prospective study
    M Scartozzi, R Giampieri, A Mandolesi, KM Abouelkhair, C Loretelli, ...
    EUROPEAN JOURNAL OF CANCER 49, S562-S562 , 2013
    2013